Adverse Event Signal Detection Using Patients' Concerns in Pharmaceutical Care Records: Evaluation of Deep Learning Models.

Journal: Journal of medical Internet research
PMID:

Abstract

BACKGROUND: Early detection of adverse events and their management are crucial to improving anticancer treatment outcomes, and listening to patients' subjective opinions (patients' voices) can make a major contribution to improving safety management. Recent progress in deep learning technologies has enabled various new approaches for the evaluation of safety-related events based on patient-generated text data, but few studies have focused on the improvement of real-time safety monitoring for individual patients. In addition, no study has yet been performed to validate deep learning models for screening patients' narratives for clinically important adverse event signals that require medical intervention. In our previous work, novel deep learning models have been developed to detect adverse event signals for hand-foot syndrome or adverse events limiting patients' daily lives from the authored narratives of patients with cancer, aiming ultimately to use them as safety monitoring support tools for individual patients.

Authors

  • Satoshi Nishioka
    Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.
  • Satoshi Watabe
    Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Yuki Yanagisawa
    Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Kyoko Sayama
    Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Hayato Kizaki
    Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.
  • Shungo Imai
    Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Mitsuhiro Someya
    Nakajima Pharmacy, Hokkaido, Japan.
  • Ryoo Taniguchi
    Nakajima Pharmacy, Hokkaido, Japan.
  • Shuntaro Yada
    Graduate School of Science and Technology, Nara Institute of Science and Technology, Ikoma, Nara, Japan.
  • Eiji Aramaki
    Nara Institute of Science and Technology (NAIST), Japan.
  • Satoko Hori
    Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.